Stocks

Mutual Fund Investments in Debt Securities Lowest in 5 Years

by

Gold Silver Reports (GSR) – Mutual Fund Investments in Debt Securities Lowest in 5 Years – Mutual funds pulled out ₹ 14,085.55 crore from debt securities in May, regulatory data showed, shifting to equities amid rising bond yields and higher fixed deposit rates. According Securities and Exchange Board of India (Sebi), this is the lowest mutual fund investment in debt markets since July 2013. In comparison, debt securities saw mutual fund inflows of ₹ 20,164.82 crore in April and ₹ 9,514.37 crore in May 2017.

Read more →

Ajanta Pharma Share Price – Keep Eye on ₹1018 level Below No Buying @all – Sell 1Laks, 2 Laks Lots – Aur So Jaaooooooooo – Hint Call By Market Guru Neal Bhai

by

Ajanta Pharma Share Price – Keep Eye on ₹1018 level Below No Buying @all – Sell 1Laks, 2 Laks Lots – Aur So Jaaooooooooo – Hint Call By Market Guru Neal Bhai

“No Magic, No Miracle, Just Power of Level”

Neal Bhai Reports (NBR) By CFA’s  and MFA’s Technical Team

Mobile No. 9582247600 & 9899900589

Read more →

Cipla Rises On U.S. FDA Nod For Immunodeficiency Drug

by

Neal Bhai Reports (NBR) — Cipla Rises On U.S. FDA Nod For Immunodeficiency Drug – Shares of the Mumbai-based drugmaker rose as much as 6.47 percent to Rs 622.75 after U.S. FDA gave its final approval to Efavirenz tablets in strength of 600 mg. Efavirenz Tablets 600 mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s Sustiva which is used in treatment of human immunodeficiency virus type 1 infection, Cipla said in an exchange filing.

Read more →